The Asia Pacific Onychomycosis Market should witness market growth of 5.6% CAGR during the forecast period (2022-2028).
Onychomycosis is frequently thought of as merely a cosmetic issue. However, it can be unpleasant, cause cellulitis in elderly people, and can result in foot ulcers in diabetic patients. The key to enhancing the appearance and preventing these consequences is the eradication of the infection. But this is difficult to do because keratin, the substance that makes up nails and is nonvascular and impervious to many substances, makes it difficult to do. As a result, topical and oral medications are mostly preferred to treat the condition.
The type of treatment depends on the organism involved, how severe the nail alterations are, and any potential side effects or drug interactions. On the basis of cure characteristics that are specified differently between researches, treatments also range in their effectiveness. Recurrent infection is possible even for those who seem to be treated, and it can happen for various reasons. Concomitant disease, genetics, immunosuppression, improper dosage or course of therapy, dampness, occlusive footwear, advanced age, poor cleanliness, tinea pedis, and trauma are some majorrisk factors.
Controlling the transmission of infectious diseases, such as HIV,continues to be difficult in many Asian countries. New illnesses and drug-resistant forms of health issuesare particularly prone to spreading in Southeast Asia. Asia, where over two-thirds of the world's poor reside, nevertheless experiences food insecurity. Southeast Asia is experiencing rapid changes in its population, agriculture, and food systems, which have led to an increase in thedevelopment of common infections resistant to last-resort antibiotics. Therefore, in the coming years, the demand for onychomycosis treatment would increase, which will expedite the growth of the regional market.
The China market dominated the Asia Pacific Onychomycosis Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $328.1 Million by 2028. The Japan market is estimated to grow a CAGR of 5% during (2022-2028). Additionally, The India market would experience a CAGR of 6.3% during (2022-2028).
Based on Type, the market is segmented into Distal Subungual, Proximal Subungual, White Superficial and Others. Based on Treatment, the market is segmented into Topical, Oral and Others. Based on countries, the market is segmented into China, Japan, India, Australia, South Korea, Singapore, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Abbott Laboratories, Bausch Health Companies, Inc., Bayer AG, Cipla Limited, Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., and GlaxoSmithKline PLC.
Onychomycosis is frequently thought of as merely a cosmetic issue. However, it can be unpleasant, cause cellulitis in elderly people, and can result in foot ulcers in diabetic patients. The key to enhancing the appearance and preventing these consequences is the eradication of the infection. But this is difficult to do because keratin, the substance that makes up nails and is nonvascular and impervious to many substances, makes it difficult to do. As a result, topical and oral medications are mostly preferred to treat the condition.
The type of treatment depends on the organism involved, how severe the nail alterations are, and any potential side effects or drug interactions. On the basis of cure characteristics that are specified differently between researches, treatments also range in their effectiveness. Recurrent infection is possible even for those who seem to be treated, and it can happen for various reasons. Concomitant disease, genetics, immunosuppression, improper dosage or course of therapy, dampness, occlusive footwear, advanced age, poor cleanliness, tinea pedis, and trauma are some majorrisk factors.
Controlling the transmission of infectious diseases, such as HIV,continues to be difficult in many Asian countries. New illnesses and drug-resistant forms of health issuesare particularly prone to spreading in Southeast Asia. Asia, where over two-thirds of the world's poor reside, nevertheless experiences food insecurity. Southeast Asia is experiencing rapid changes in its population, agriculture, and food systems, which have led to an increase in thedevelopment of common infections resistant to last-resort antibiotics. Therefore, in the coming years, the demand for onychomycosis treatment would increase, which will expedite the growth of the regional market.
The China market dominated the Asia Pacific Onychomycosis Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $328.1 Million by 2028. The Japan market is estimated to grow a CAGR of 5% during (2022-2028). Additionally, The India market would experience a CAGR of 6.3% during (2022-2028).
Based on Type, the market is segmented into Distal Subungual, Proximal Subungual, White Superficial and Others. Based on Treatment, the market is segmented into Topical, Oral and Others. Based on countries, the market is segmented into China, Japan, India, Australia, South Korea, Singapore, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Abbott Laboratories, Bausch Health Companies, Inc., Bayer AG, Cipla Limited, Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., and GlaxoSmithKline PLC.
Scope of the Study
By Type
- Distal Subungual
- Proximal Subungual
- White Superficial
- Others
By Treatment
- Topical
- Oral
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Australia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Abbott Laboratories
- Bausch Health Companies, Inc.
- Bayer AG
- Cipla Limited
- Merck & Co., Inc.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- GlaxoSmithKline PLC
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Onychomycosis Market, by Type
1.4.2 Asia Pacific Onychomycosis Market, by Treatment
1.4.3 Asia Pacific Onychomycosis Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Onychomycosis Market by Type
3.1 Asia Pacific Distal Subungual Market by Country
3.2 Asia Pacific Proximal Subungual Market by Country
3.3 Asia Pacific White Superficial Market by Country
3.4 Asia Pacific Others Market by Country
Chapter 4. Asia Pacific Onychomycosis Market by Treatment
4.1 Asia Pacific Topical Market by Country
4.2 Asia Pacific Oral Market by Country
4.3 Asia Pacific Others Market by Country
Chapter 5. Asia Pacific Onychomycosis Market by Country
5.1 China Onychomycosis Market
5.1.1 China Onychomycosis Market by Type
5.1.2 China Onychomycosis Market by Treatment
5.2 Japan Onychomycosis Market
5.2.1 Japan Onychomycosis Market by Type
5.2.2 Japan Onychomycosis Market by Treatment
5.3 India Onychomycosis Market
5.3.1 India Onychomycosis Market by Type
5.3.2 India Onychomycosis Market by Treatment
5.4 Australia Onychomycosis Market
5.4.1 Australia Onychomycosis Market by Type
5.4.2 Australia Onychomycosis Market by Treatment
5.5 South Korea Onychomycosis Market
5.5.1 South Korea Onychomycosis Market by Type
5.5.2 South Korea Onychomycosis Market by Treatment
5.6 Singapore Onychomycosis Market
5.6.1 Singapore Onychomycosis Market by Type
5.6.2 Singapore Onychomycosis Market by Treatment
5.7 Rest of Asia Pacific Onychomycosis Market
5.7.1 Rest of Asia Pacific Onychomycosis Market by Type
5.7.2 Rest of Asia Pacific Onychomycosis Market by Treatment
Chapter 6. Company Profiles
6.1 Abbott Laboratories
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 SWOT Analysis
6.2 Bausch Health Companies, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.2.5 Recent strategies and developments:
6.2.5.1 Trials and Approvals:
6.3 Bayer AG
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Product Launches and Expansions:
6.4 Cipla Limited
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Product Launches and Product Expansions:
6.5 Sun Pharmaceutical Industries Ltd.
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Regional & Segmental Analysis
6.5.4 Research & Development Expenses
6.5.5 Recent strategies and developments:
6.5.5.1 Acquisition and Mergers:
6.6 GlaxoSmithKline PLC (GSK)
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.6.5 Recent strategies and developments:
6.6.5.1 Partnerships, Collaborations, and Agreements:
6.7 Pfizer, Inc.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional & Segmental Analysis
6.7.4 Research & Development Expense
6.8 Teva Pharmaceutical Industries Ltd.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expenses
6.9 Merck & Co., Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expenses
6.10. Novartis AG
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Segmental and Regional Analysis
6.10.4 Research & Development Expense
Companies Mentioned
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Abbott Laboratories
- Bausch Health Companies, Inc.
- Bayer AG
- Cipla Limited
- Merck & Co., Inc.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- GlaxoSmithKline PLC
Methodology
LOADING...
